NEW YORK (GenomeWeb News) – Teva Pharmaceuticals will be the exclusive distributor of MDxHealth's tests for prostate cancer and glioblastoma in Israel under a deal announced today.

The three-year agreement provides Teva the exclusive rights to distribute MDxHealth's ConfirmMDx for Prostate Cancer and PredictMDx for Glioblastoma in Israel. MDxHealth will analyze samples in its CLIA-registered laboratory in Irvine, Calif., and Teva will reimburse MDxHealth for all testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.